Blog

Editas stock jumps after Broad wins CRISPR patent fight – FierceBiotech


FierceBiotech

Editas stock jumps after Broad wins CRISPR patent fight
FierceBiotech
Shares in Editas Medicine rose 30% after the U.S. patent office sided with the Broad Institute in the legal tussle over CRISPR gene editing. The board ruled that the inventions claimed by the Broad and the University of California are distinct

and more »

2017-02-16 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.